256 related articles for article (PubMed ID: 32992842)
1. High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.
Torrente L; Maan G; Oumkaltoum Rezig A; Quinn J; Jackson A; Grilli A; Casares L; Zhang Y; Kulesskiy E; Saarela J; Bicciato S; Edwards J; Dinkova-Kostova AT; de la Vega L
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32992842
[TBL] [Abstract][Full Text] [Related]
2. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
[TBL] [Abstract][Full Text] [Related]
3. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
4. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Tanaka R; Squires MS; Kimura S; Yokota A; Nagao R; Yamauchi T; Takeuchi M; Yao H; Reule M; Smyth T; Lyons JF; Thompson NT; Ashihara E; Ottmann OG; Maekawa T
Blood; 2010 Sep; 116(12):2089-95. PubMed ID: 20548094
[TBL] [Abstract][Full Text] [Related]
5. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
6. The role of Nrf2-Keap1 axis in colorectal cancer, progression, and chemoresistance.
Sadeghi MR; Jeddi F; Soozangar N; Somi MH; Samadi N
Tumour Biol; 2017 Jun; 39(6):1010428317705510. PubMed ID: 28621229
[TBL] [Abstract][Full Text] [Related]
7. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
8. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling.
Iuchi K; Tasaki Y; Shirai S; Hisatomi H
Biomed Pharmacother; 2020 May; 125():109928. PubMed ID: 32004978
[TBL] [Abstract][Full Text] [Related]
10. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
11. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
[TBL] [Abstract][Full Text] [Related]
12. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
[TBL] [Abstract][Full Text] [Related]
13. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Kim HG; Kim CW; Lee DH; Lee JS; Oh ET; Park HJ
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491980
[TBL] [Abstract][Full Text] [Related]
14. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
15. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
16. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
Petersen W; Liu J; Yuan L; Zhang H; Schneiderjan M; Cho YJ; MacDonald TJ
Cancer Lett; 2014 Nov; 354(1):68-76. PubMed ID: 25107642
[TBL] [Abstract][Full Text] [Related]
18. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Shah M; Gallipoli P; Lyons J; Holyoake T; Jørgensen H
Blood Cells Mol Dis; 2012 Mar; 48(3):199-201. PubMed ID: 22325915
[No Abstract] [Full Text] [Related]
19. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
20. Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.
Moawad EY
J Gastrointest Cancer; 2015 Dec; 46(4):380-9. PubMed ID: 26346504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
